DrugPatentWatch Database Preview
Drugs in Development Information for Tegobuvir
» See Plans and Pricing
What is the drug development status for Tegobuvir?
Tegobuvir is an investigational drug.
There have been 5 clinical trials for Tegobuvir.
The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2011.
The most common disease conditions in clinical trials are Hepatitis C, Chronic, Hepatitis C, and Hepatitis A. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
There are twenty-five US patents protecting this investigational drug and four hundred and four international patents.
Summary for Tegobuvir
| US Patents | 25 |
| International Patents | 404 |
| US Patent Applications | 45 |
| WIPO Patent Applications | 193 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2011-07-01) |
| Vendors | 37 |
Recent Clinical Trials for Tegobuvir
| Title | Sponsor | Phase |
|---|---|---|
| GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
| GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
| Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Tegobuvir
Top disease conditions for Tegobuvir
Top clinical trial sponsors for Tegobuvir
US Patents for Tegobuvir
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Tegobuvir | Start Trial | Method for treating HCV | AbbVie Inc. (North Chicago, IL) | Start Trial |
| Tegobuvir | Start Trial | Methods for treating HCV | Gilead Pharmasset LLC (Foster City, CA) | Start Trial |
| Tegobuvir | Start Trial | Pyridazine compound and use thereof | Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AU) | Start Trial |
| Tegobuvir | Start Trial | Pyridazine compound and use thereof | Gilead Sciences, Inc. (Foster City, CA) K.U. Leuven Research & Development (Leuven, BE) Gerhard Puerstinger (Igls, AT) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Tegobuvir
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Tegobuvir | Australia | AU2014239563 | 2033-03-14 | Start Trial |
| Tegobuvir | Australia | AU2015240754 | 2033-03-14 | Start Trial |
| Tegobuvir | Australia | AU2016202823 | 2033-03-14 | Start Trial |
| Tegobuvir | Australia | AU2016291154 | 2033-03-14 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
